Novartis announces FDA approval for JadenuTM for patients with chronic iron overload
Novartis announced the FDA has approved JadenuTM (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. March 30, 2015